

## NÖTROPENİ

*Doç. Dr. Gülbeyaz Can*

### ÖĞRENİM HEDEFLERİ

Bu bölüm sonunda okuyucu;

1. Hematopoez sürecini bilir,
2. Nütropeni tanımlar,
3. Febril nütropenide tanılama ve fizik muayeneyi yapar,
4. Febril nütropenili hastanın bakımını yapar.

### GİRİŞ

Onkolojide ve hematoloji hastalarında sık görülen nütropeni, periferik kandaki nötrofil sayısının düşmesi olarak tanımlanır. Gelişimi hastaya, hastalığa ve tedaviye ilişkin pek çok neden ile ilişkilidir. Genellikle hastada hastalığa bağlı kemik iliği tutulumunun olması ya da hastanın hematolojik malignite tanısı ile tedavi görmesi, tedavisinde yüksek doz kemoterapi alması, kemik iliğini içeren alanların ışınlanması ya da hastaya kök hücre nakli yapılması ile gelişmektedir. Hastanın yaşlı olması, hastada ko-morbid hastalığın olması, hastanın performans durumunun düşük olması, tedavi sırasında gıda alımının yetersiz olması ve öncesinde nütropeni hikâyesinin olması bu sorunun gelişme riskini artırmaktadır. Neden ne olursa olsun, son yıllarda kanser tedavisindeki gelişmeler daha yoğun tedavi rejimlerinin kullanma olanağını arttırdığından kanser tedavisinin herhangi bir aşamasında tüm kanser hastalarında nütropeni gelişme riski yüksektir. Önemli

## KAYNAKLAR

1. Keskin S, Eralp Y. Onkolojik Aciller. Klinik Gelişim. 2011; 24:10-13
2. Vioral A, Wentley D. Managing Oncology Neutropenia and Sepsis in the Intensive Care. Crit Care Nurs Q. 2015;38(2):165-74.
3. Souza-Dantas VC, Salluh JI, Soares M. Impact of neutropenia on the outcomes of critically ill patients with cancer: a matched case-control study. Ann Oncol 2011;22(9):2094–100.
4. Zafrani L, Azoulay E. How to treat severe infections in critically ill neutropenic patients? BMC Infect Dis. 2014;14:512
5. Aygencel G, Turkoglu M, Sucak GT, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. Journal of Critical Care 2014;29: 618–626
6. Bird GT, Farquhar-Smith P, Wigmore T, Potter M, Gruber PC. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: a 5 yr study. Br J Anaesth. 2012;108(3):452-9.
7. McCaughey C, Blackwood B, Glackin M, Brady M, McMullin MF. Characteristics and outcomes of haematology patients admitted to the intensive care unit. Nurs Crit Care 2013;18(4):193-9.
8. Mokart D, Darmon M, Resche-Rigon M, Lemiale V, Pène F, Mayaux J, et al. Prognosis of neutropenic patients admitted to the intensive care unit. Intensive Care Med. 2015;41(2):296-303.
9. Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med 2003;31(1):104–12.
10. Namendys-Silva SA, González-Herrera MO, García-Guillén FJ, Texcocano-Becerra J, Herrera-Gómez A. Outcome of critically ill patients with hematological malignancies. Ann Hematol 2013;92(5):699–705.
11. Owczuk R, Wujtewicz MA, Sawicka W, Wadzyk A, Wujtewicz M. Patients with haematological malignancies requiring invasive mechanical ventilation: differences between survivors and nonsurvivors in intensive care unit. Support Care Cancer 2005;13(5):332-8
12. Zafrani L, Elie Azoulay E. How to treat severe infections in critically ill neutropenic patients? BMC Infect Dis 2014; 14: 512.
13. National Cancer Institute - Common Terminology Criteria for Adverse Events v4.03: (CTCAE), June 14, 2010, [http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE\\_4.03\\_2010-06-14\\_QuickReference\\_5x7.pdf](http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf) (Ulaşım tarihi: 15/06/2015).
14. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The multinational association for supportive care in cancer risk index. A multinational scoring system for identifying low risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18:3038-3051.
15. Gülezer GN, Özdemir EE, Atay S, Korkmaz K, Pınar R, Kebudi R. Nötropeni. Ed. G. Can, Onkoloji Hemşireliğinde Kanıttan Uygulamaya – Konsensus 2014, 1. Baskı, İstanbul, Nobel Tıp Kitabevleri, 2015, 79-94.
16. Buchheidt D, Hummel M, Engelich G, Hehlmann R. Management of infections in critically ill neutropenic cancer patients. J Crit Care 2004;19(3):165-73.

17. Penack O, Buchheidt D, Christopheit M, von Lilienfeld-Toal M, Massenkeil G, Hentrich M, et al. Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology. *Ann Oncol* 2011;22(5):1019–1029.
18. Zitella L, Gobel BH, O'Leary C, Belansky H. Prevention of infection. In: Eaton LH, Tipton JM, eds. *Putting Evidence Into Practice: Improving Oncology Patient Outcomes*. Pittsburgh, PA: Oncology Nursing Society; 2009:273–283.
19. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. Version 2.2014. [http://www.nccn.org/professionals/physician\\_gls/PDF/myeloid\\_growth.pdf](http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf) (Erişim tarihi: 14.06.2015)
20. Atay S. Nötropeni ve Enfeksiyon, ed. G. Can, *Onkoloji Hemşireliği*, 1. Baskı, Nobel Tıp Kitapevleri, İstanbul, 2015, 347-354.
21. Karakurt S. Bağışıklık Sistemi Baskılanmış Hastalarda Yoğun Bakım. *Yoğun Bakım Dergisi* 2006;6(1):5-15
22. Lucet JC, Rigaud MP, Mentre F, Kassis N, Deblangy C, Andremont A, Bouvet E. Hand contamination before and after different hand hygiene techniques: a randomized clinical trial. *J Hosp Infect* 2002; 50(4):276-280.
23. Kac G, Podglajen I, Gueneret M, Vaupré S, Bissery A, Meyer G. Microbiological evaluation of two hand hygiene procedures achieved by healthcare workers during routine patient care: a randomized study. *J Hosp Infect* 2005; 60:32-39.
24. Oughton MT, Loo VG, Dendukuri N, Fenn S, Libman MD. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of *Clostridium difficile*. *Infect Control Hosp Epidemiol*. 2009; 30(10):939-944.
25. Jabbar U, Leischner J, Kasper D, Gerber R, Sambol SP, Parada JP, et al. Effectiveness of alcohol-based hand rubs for removal of *Clostridium difficile* spores from hands. *Infect Control Hosp Epidemiol* 2010; 31(6):565-670.
26. Boyce JM, Ligi C, Kohan C, Dumigan D, Havill NL. Lack of association between the increased incidence of *Clostridium difficile*-associated disease and the increasing use of alcohol-based hand rubs. *Infect Control Hosp Epidemiol*, 2006; 27(5):479-483.
27. Vernaz N, Sax H, Pittet D, Bonnabry P, Schrenzel J, Harbarth S. Temporal effects of antibiotic use and hand rub consumption on the incidence of MRSA and *Clostridium difficile*. *J Antimicrob Chemother* 2008; 62(3):601-607.
28. Kaier K, Hagist C, Frank U, Conrad A, Meyer E. Two time-series analyses of the impact of antibiotic consumption and alcohol-based hand disinfection on the incidences of nosocomial methicillin-resistant *Staphylococcus aureus* infection and *Clostridium difficile* infection. *Infect Control Hosp Epidemiol*. 2009; 30(4):346-353.
29. De Angelis, Cataldo MA, De Waure C, Venturiello S, La Torre G, Cauda R, et al. Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. *J Antimicrob Chemother* 2014; 69(5):1185-1192.
30. Boyce JM, Pittet D. Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. *MMWR Recomm Rep*. 2002; 25:51(RR-16):1-45.
31. WHO Guidelines on Hand Hygiene in Health Care. World Health Organization 2009, <http://www.who.int/gpsc/5may/tools/9789241597906/en/> (Erişim tarihi 16.06.2015)

32. Berry AM, Davidson PM, Nicholson L, Pasqualotto C, Rolls K. Consensus based clinical guideline for oral hygiene in the critically ill. *Intensive & Critical Care Nursing* 2011; 27: 180–185.
33. Andrews T, Steen C. A review of oral preventative strategies to reduce ventilator-associated pneumonia. *Nurs Crit Care*. 2013;18(3):116-22.
34. Chan EY, Ruest AO, Meade M. Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. *BMJ* 2007; 334: 889–893.
35. Chen W, Li S, Li L, Wu X, Zhang W. Effects of daily bathing with chlorhexidine and acquired infection of methicillin-resistant *Staphylococcus aureus* and vancomycin-resistant *Enterococcus*: a meta-analysis. *J Thorac Dis* 2013; 5(4):518-524.
36. O'Horo JC, Silva GL, Munoz-Price LS, Safdar N. The efficacy of daily bathing with chlorhexidine for reducing healthcare-associated bloodstream infections: a meta-analysis. *Infect Control Hosp Epidemiol* 2012; 33(3):257-267.
37. Viray MA, Morley JC, Coopersmith CM, Kollef MH, Fraser VJ, et al. Daily bathing with chlorhexidine-based soap and the prevention of *Staphylococcus aureus* transmission and infection. *Infect Control Hosp Epidemiol* 2014; 35(3):243-250.
38. Milstone AM, Elward A, Song X, Zerr DM, Orscheln R, Speck K, et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, cluster-randomised, crossover trial. *Lancet* 2013; 381(9872):1099-10106.
39. Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. *N Engl J Med* 2013; 368(6):533-542.
40. Schiffer CA, Mangu PB, Wade JC, Camp-Sorrell D, Cope DG, El-Rayes BF, et al. Central Venous Catheter Care for the Patient With Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *American Society of Clinical Oncology*. 2013; 31(10):1357-1370.
41. Gardner A, Mattiuzzi G, Faderl S, Borthakur G, Garcia-Manero G, Pierce S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. *J Clin Oncol*. 2008;26(35):5684–5688.
42. van Tiel F, Harbers MM, Terporten PH, van Boxtel RT, Kessels AG, Voss GB, Schouten HC. Normal hospital and low-bacterial diet in patients with cytopenia after intensive chemotherapy for hematologic malignancy: a study of safety. *Ann Oncol* 2007;18(6):1080–1084.
43. Gobel BH, Peterson GJ. Sepsis and septic shock. *Clin J Oncol Nurs* 2010;14(6):793–797.
44. Dellinger RP, Levy M, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Intensive Care Med* 2008;34:17–60.
45. Azoulay E, Schlemmer B. Diagnostic strategy in cancer patients with acute respiratory failure. *Intensive Care Med* 2006;32(6):808–822.
46. Shi Z, Xie H, Wang P, Zhang Q, Wu Y, Chen E, Ng L, Worthington HV, Needleman I, Furness S. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. *Cochrane Database Syst Rev* 2013 Aug 13;8:CD008367.
47. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, Lemiale V, Seguin A, Darmon M, Schlemmer B, Azoulay E. Survival in neutropenic patients with severe sepsis or septic shock. *Crit Care Med* 2012;40(1):43–49.